The podcast features an interview with Eli Lilly CEO Dave Ricks, discussing the company's journey and success with GLP-1 drugs like Terzepatide (Manjaro), including its initial development, market impact, and future prospects. Ricks addresses concerns about pricing, counterfeit drugs, and the moral imperative to make these medications more accessible, while balancing the need for continued R&D investment. The conversation also explores the potential of GLP-1s for treating mental health conditions, the broken biotech market, the role of PBMs, and the need for healthcare system reforms, including the food system and consumer engagement, and touches on lifestyle routines and the future of research funding.
Sign in to continue reading, translating and more.
Continue
